- Home
- SPCE vs IKT Comparison
SPCE vs IKT Comparison
Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- IKT
- Stock Information
- Founded
- SPCE 2017
- IKT 2008
- Country
- SPCE United States
- IKT United States
- Employees
- SPCE N/A
- IKT N/A
- Industry
- SPCE Transportation Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- IKT Health Care
- Exchange
- SPCE Nasdaq
- IKT Nasdaq
- Market Cap
- SPCE 187.1M
- IKT 159.2M
- IPO Year
- SPCE N/A
- IKT 2020
- Fundamental
- Price
- SPCE $5.15
- IKT $2.72
- Analyst Decision
- SPCE Hold
- IKT Strong Buy
- Analyst Count
- SPCE 6
- IKT 2
- Target Price
- SPCE $25.50
- IKT $6.50
- AVG Volume (30 Days)
- SPCE 1.8M
- IKT 288.1K
- Earning Date
- SPCE 02-25-2025
- IKT 11-14-2024
- Dividend Yield
- SPCE N/A
- IKT N/A
- EPS Growth
- SPCE N/A
- IKT N/A
- EPS
- SPCE N/A
- IKT N/A
- Revenue
- SPCE $9,416,000.00
- IKT $1.00
- Revenue This Year
- SPCE $5.88
- IKT N/A
- Revenue Next Year
- SPCE N/A
- IKT N/A
- P/E Ratio
- SPCE N/A
- IKT N/A
- Revenue Growth
- SPCE 93.74
- IKT N/A
- 52 Week Low
- SPCE $5.06
- IKT $1.12
- 52 Week High
- SPCE $43.20
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- SPCE 31.51
- IKT 41.71
- Support Level
- SPCE $5.23
- IKT $2.55
- Resistance Level
- SPCE $6.74
- IKT $2.90
- Average True Range (ATR)
- SPCE 0.36
- IKT 0.29
- MACD
- SPCE -0.09
- IKT -0.08
- Stochastic Oscillator
- SPCE 5.26
- IKT 18.09
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.